Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a
high social cost. Depressed patients generally display co-morbid symptoms, and depression …

The past decade has seen a steady accumulation of evidence supporting a role for the
excitatory amino acid (EAA) neurotransmitter, glutamate, and its receptors in depression and …

There are marked sex differences in the prevalence, phenotypic presentation and treatment
response for major depression. While genome-wide association studies (GWAS) adjust for …

Recent compelling evidence has suggested that the glutamate system is a primary mediator
of psychiatric pathology and also a target for rapid-acting antidepressants. Clinical research …

The mechanisms of action of the rapid antidepressant effects of ketamine, an N-methyl-D-
aspartate glutamate receptor antagonist, have not been fully elucidated. This study …

Depression and anxiety represent a major problem. However, the current treatment of both
groups of diseases is not satisfactory. As the glutamatergic system may play an important …

Medicinal therapies for mood disorders neither fully serve the efficacy needs of patients nor
are they free of side-effect issues. Although monoamine-based therapies are the primary …

Contrary to existing evidence, convulsant liability of the antidepressants has been attributed
to noradrenergic and serotonergic increments. This is a classic case of confusing treatment …

The mammalian central nervous system derives from multipotent neural progenitor cells
(NPCs) of the developing brain. During development the progenitor cells have enormous …

Background Preclinical and postmortem studies have implicated the metabotropic glutamate
receptor 5 (mGluR5) in the pathophysiology of major depressive disorder (MDD). The goal …